BNGO vs. DAIO, PRPO, MSAI, STAI, ASTC, TLIS, SMIT, SPEC, TBIO, and THMO
Should you be buying Bionano Genomics stock or one of its competitors? The main competitors of Bionano Genomics include Data I/O (DAIO), Precipio (PRPO), MultiSensor AI (MSAI), ScanTech AI Systems (STAI), Astrotech (ASTC), Talis Biomedical (TLIS), Schmitt Industries (SMIT), Spectaire (SPEC), Telesis Bio (TBIO), and ThermoGenesis (THMO). These companies are all part of the "measuring and control equipment" industry.
Bionano Genomics vs. Its Competitors
Data I/O (NASDAQ:DAIO) and Bionano Genomics (NASDAQ:BNGO) are both small-cap measuring and control equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.
37.0% of Data I/O shares are held by institutional investors. Comparatively, 11.4% of Bionano Genomics shares are held by institutional investors. 2.6% of Data I/O shares are held by insiders. Comparatively, 0.9% of Bionano Genomics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Data I/O has a net margin of -11.49% compared to Bionano Genomics' net margin of -271.02%. Data I/O's return on equity of -14.60% beat Bionano Genomics' return on equity.
Data I/O has higher earnings, but lower revenue than Bionano Genomics. Data I/O is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.
Data I/O has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, Bionano Genomics has a beta of 2.25, suggesting that its stock price is 125% more volatile than the S&P 500.
Data I/O currently has a consensus target price of $5.22, suggesting a potential upside of 54.44%. Bionano Genomics has a consensus target price of $7.50, suggesting a potential upside of 351.81%. Given Bionano Genomics' higher possible upside, analysts plainly believe Bionano Genomics is more favorable than Data I/O.
In the previous week, Data I/O and Data I/O both had 2 articles in the media. Data I/O's average media sentiment score of 1.89 beat Bionano Genomics' score of 0.95 indicating that Data I/O is being referred to more favorably in the media.
Summary
Data I/O beats Bionano Genomics on 10 of the 14 factors compared between the two stocks.
Get Bionano Genomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNGO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BNGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bionano Genomics Competitors List
Related Companies and Tools
This page (NASDAQ:BNGO) was last updated on 9/27/2025 by MarketBeat.com Staff
